-
1دورية أكاديمية
المؤلفون: Thiry, Nancy
المساهمون: De Laet, Chris, Hulstaert, Frank, Neyt, Mattias, Huybrechts, Michel, Cleemput, Irina
مصطلحات موضوعية: W 1 Serials. Periodicals, Journal Article, Peer Review, Great Britain, Adolescent, Adult, Belgium, Child, Cohort Studies, Cost-Benefit Analysis, Female, Humans, Health Care Costs, Markov Chains, Mass Screening, Papillomavirus Vaccines, Quality-Adjusted Life Years
الوصف: 161-170 ; OBJECTIVES: The cost-effectiveness of adding a human papillomavirus (HPV) vaccination program in 12-year-old females to the recommended cervical cancer screening in Belgium is examined. Moreover, the health and economic consequences of a potential decline in screening uptake after initiation of a HPV vaccination program are investigated. METHODS: A static Markov model is developed to estimate the direct effect of vaccination on precancerous lesions and cervical cancers. RESULTS: Vaccination is estimated to avoid 20 percent of the cervical cancers occurring in a 12-year-old girls' cohort and to cost 32,665 euro per quality-adjusted life-year (QALY) gained (95 percent credibility interval [CrI]: 17,447 euro to 68,078 euro), assuming a booster injection after 10 years, a limited duration of protection and discounting costs and effects at 3 percent and 1.5 percent, respectively. Assuming lifelong protection, HPV vaccination is estimated to cost 14,382 euro (95 percent CrI: 9,238 euro to 25,644 euro) per QALY gained, while avoiding 50 percent of the cervical cancer cases. In the base-case, a 10 percent reduction in screening compliance after vaccination obliterates the effect of vaccination on cervical cancer cases avoided, whereas further declines in the level of screening compliance even turned out to be detrimental for the cohort's health, inducing a mean loss in QALYs and life-year gained compared with the situation prevaccination. CONCLUSIONS: An HPV vaccination program should only be considered if the level of screening after vaccination can be maintained.
العلاقة: Vignette : https://kce.docressources.info/thumbnail.php?typeTest=1&id=2200; https://kce.docressources.info/index.php?lvl=notice_display&id=2200Test; 2200
-
2دورية أكاديمية
المؤلفون: Peetermans, W.E.
المساهمون: Van de Vyver, N, Van Laethem, Y., Van Damme, Pierre, Thiry, Nancy, Trefois, P., Geerts, P., Schetgen, M., Peleman, R, Swennen, B., Verhaegen, J.
مصطلحات موضوعية: administration and dosage, Adult, Aged, Belgium, complications, Cost-Benefit Analysis, Economics, Humans, Journal Article, Peer Review, Pneumococcal Infections, Pneumococcal Vaccines, Practice Guideline [Publication type], prevention and control, Treatment outcome, W 1 Serials. Periodicals
الوصف: 329-337 ; A multidisciplinary expert panel, appointed by the High Council for Public Health, evaluated the scientific evidence on which the recommendations for the appropriate use of the pneumococcal vaccine was based and reviewed the studies that became available since previous reports. The conclusions of the working group, presented in this manuscript, resulted in an update of the Belgian recommendations for pneumococcal vaccination.
العلاقة: Vignette : https://kce.docressources.info/thumbnail.php?typeTest=1&id=1770; https://kce.docressources.info/index.php?lvl=notice_display&id=1770Test; 1770
